Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection | Zendy

Amitis Ramezani | Zendy; Ali Akbar Velayati | Zendy; Mohammad Reza Hasanjani Roshan | Zendy; Latif Gachkar | Zendy; Mohammad Banifazl | Zendy; Hossein Keyvani | Zendy; Arezoo Aghakhani | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection

Author(s) -

Amitis Ramezani,

Ali Akbar Velayati,

Mohammad Reza Hasanjani Roshan,

Latif Gachkar,

Mohammad Banifazl,

Hossein Keyvani,

Arezoo Aghakhani

Publication year - 2008

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2007.08.003

Subject(s) - lamivudine , medicine , virology , hbeag , chronic hepatitis , hepatitis b virus , virus , mutant , hepatitis b , gastroenterology , biology , gene , hbsag , genetics

Lamivudine is used for the treatment of chronic hepatitis B patients. Recent studies show that the YMDD motif mutants (resistant hepatitis B virus) occur as natural genome variability in lamivudine-untreated chronic hepatitis B patients. In this study we aimed to determine the rate of YMDD motif mutants in lamivudine-untreated chronic hepatitis B patients in Iran.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research